PHVS (Pharvaris NV) ROE % Adjusted to Book Value : -17.66% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Pharvaris NV ROE % Adjusted to Book Value?

Pharvaris NV's ROE % for the quarter that ended in Sep. 2024 was -53.86%. Pharvaris NV's PB Ratio for the quarter that ended in Sep. 2024 was 3.05. Pharvaris NV's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -17.66%.

Pharvaris NV ROE % Adjusted to Book Value Historical Data

The historical data trend for Pharvaris NV's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharvaris NV ROE % Adjusted to Book Value Chart

Pharvaris NV Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-13.47

-17.22

-10.90

Pharvaris NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-10.96	-14.02	-9.44	-12.08	-17.66

Competitive Comparison of Pharvaris NV's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Pharvaris NV's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharvaris NV's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharvaris NV's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Pharvaris NV's ROE % Adjusted to Book Value falls into.

Pharvaris NV ROE % Adjusted to Book Value Calculation

Pharvaris NV's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-38.14%	/	3.50
	=	-10.90%

Pharvaris NV's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-53.86%	/	3.05
	=	-17.66%

Pharvaris NV ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Pharvaris NV's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharvaris NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (NAS:PHVS) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

9EN:Germany

Address

Emmy Noetherweg 2, Leiden, NLD, 2333 BK

Website

https://www.pharvaris.com

Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.